This dataset collected 40 ml of heparinized blood from 20 COVID-19 patients who were admitted to the University of Maryland Medical Center between June and August of 2020. Plasma samples were collected at a median of 10 or 7 days, dependent on the patient's risk group. Samples were analyzed using full-length recombinant protein in an enzyme-linked immunosorbent assay (ELISA). Antibodies were screened against 9 different SARS-CoV-2 proteins. Responses were observed against the spike (S) proteins, the receptor-binding domain (RBD), and the nucleocapsid (N) protein which were of the IgG1 and IgG3 subtypes. Studies using this dataset aim to identify the most relevant component of the anti-SARS-CoV-2 humoral immune response and enable researchers to design more meaningful immunomonitoring methods for anti-COVID19 vaccines.
"The GISAID Initiative promotes the rapid sharing of data from all influenza viruses and the coronavirus causing COVID-19. This includes genetic sequence and related clinical and epidemiological data associated with human viruses, and geographical as well as species-specific data associated with avian and other animal viruses, to help researchers understand how viruses evolve and spread during epidemics and pandemics. GISAID does so by overcoming disincentive hurdles and restrictions, which discourage or prevented sharing of virological data prior to formal publication." (From "Mission")